Press Release: Establishment Labs to Announce Third Quarter 2024 Financial Results on November 7
Morales Plastic Surgery Introduces Cutting-Edge Motiva Breast Implants
Mizuho Securities Maintains Establishment Labs(ESTA.US) With Buy Rating, Maintains Target Price $70
Mizuho Securities Maintains Establishment Labs(ESTA.US) With Buy Rating, Announces Target Price $70
Establishment Labs Publishes 2024 Post Market Surveillance Report
Establishment Labs Is Maintained at Buy by BTIG
BTIG Maintains Establishment Labs(ESTA.US) With Buy Rating, Raises Target Price to $65
Express News | Establishment Labs Holdings Inc : Btig Raises Target Price to $65 From $62
Strong Market Potential and Solid Financial Strategy Underpin Buy Rating for Establishment Labs Holdings
Market Participants Recognise Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Revenues
Sector Update: Health Care Stocks Decline Late Afternoon
Establishment Labs Shares Climb on High Demand for FDA-Approved Breast Motiva Implants
First U.S. Women Successfully Receive Breast Augmentation With New FDA Approved Motiva Implants
Establishment Labs Is Maintained at Neutral by Citigroup
Establishment Labs Hldgs Analyst Ratings
Citi Maintains Establishment Labs(ESTA.US) With Hold Rating, Raises Target Price to $50
Express News | Establishment Labs Holdings Inc : Citigroup Raises Target Price to $50 From $45
Mizuho Securities Maintains Establishment Labs(ESTA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Alkermes (ALKS) and Axsome Therapeutics (AXSM)
Express News | Establishment Labs Shares up 13.9% After Co Receives U.S. FDA Approval for Motiva Implants